Literature DB >> 30210978

Dural Invasion Predicts the Laterality and Development of Neck Metastases in Esthesioneuroblastoma.

John P Marinelli1, Jeffrey R Janus2, Jamie J Van Gompel2,3, Michael J Link2,3, Eric J Moore2, Kathryn M Van Abel2, Brandon W Peck2, Christine M Lohse4, Daniel L Price2.   

Abstract

Objectives  Neck metastases in patients with esthesioneuroblastoma (ENB) constitute the most significant predictor of poor long-term survival. Recently, researchers discovered the existence of dural lymphatic channels that drain to the cervical lymph nodes. From this physiologic basis, we hypothesized that patients with ENB who develop dural invasion (DI) would exhibit a proclivity for neck metastases. Design  Retrospective review. Setting  Tertiary referral center. Participants  All patients treated for ENB from January 1, 1994 to December 31, 2015. Main Outcome Measures  Incidence, laterality, and recurrence rate of neck metastases by DI status. Results  Sixty-one patients were identified (38% female; median age 49, range, 10-80), 34 (56%) of whom had DI and 27 (44%) did not. Of patients with DI, 50% presented with or developed neck disease following treatment compared with just 22% of those without DI ( p  = 0.026). Bilateral neck disease was more common in patients with DI (11/34, 32%) compared with those without (2/27, 7%) ( p  = 0.018). Five-year regional recurrence-free survival rates were 88% for those without and 64% for those with DI ( p  = 0.022). Kadish C patients with DI were more likely to develop regional recurrence when compared with Kadish C without DI and Kadish A/B ( p  = 0.083). Further, Kadish C patients with DI displayed worse overall survival than Kadish C without DI and Kadish A/B. Kadish D patients displayed the worst overall survival. The difference in overall survival among these four groups was significant ( p  < 0.001). Conclusion  DI by ENB is associated with increased incidence of cervical nodal metastases, bilateral neck disease, worse regional recurrence-free survival, and poorer overall survival. These data support the division of Kadish C by DI status.

Entities:  

Keywords:  dural invasion; elective neck treatment; esthesioneuroblastoma; neck metastases; olfactory neuroblastoma

Year:  2018        PMID: 30210978      PMCID: PMC6133676          DOI: 10.1055/s-0038-1625977

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  19 in total

1.  Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors.

Authors:  Daniel Jethanamest; Luc G Morris; Andrew G Sikora; David I Kutler
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2007-03

Review 2.  Long-term carcinologic results of advanced esthesioneuroblastoma: a systematic review.

Authors:  Guillaume De Bonnecaze; B Lepage; J Rimmer; A Al Hawat; B Vairel; E Serrano; B Chaput; S Vergez
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-17       Impact factor: 2.503

Review 3.  Esthesioneuroblastoma: a meta-analysis and review.

Authors:  P Dulguerov; A S Allal; T C Calcaterra
Journal:  Lancet Oncol       Date:  2001-11       Impact factor: 41.316

4.  Esthesioneuroblastoma: is there a need for elective neck treatment?

Authors:  Candan Demiroz; Orit Gutfeld; Mohamed Aboziada; Doris Brown; Lawrence J Marentette; Avraham Eisbruch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-15       Impact factor: 7.038

5.  Esthesioneuroblastoma: an update on the UCLA experience, 2002-2013.

Authors:  Bobby A Tajudeen; Armin Arshi; Jeffrey D Suh; Miguel Fernando Palma-Diaz; Marvin Bergsneider; Elliot Abemayor; Maie St John; Marilene B Wang
Journal:  J Neurol Surg B Skull Base       Date:  2014-09-13

6.  Volumetric analysis of olfactory neuroblastoma skull base laterality and implications on neck disease.

Authors:  John P Marinelli; Jamie J Van Gompel; Michael J Link; Eric J Moore; Daniel L Price; Katherine A Lees; Mark W Kaczor; Jeffrey R Janus
Journal:  Laryngoscope       Date:  2017-08-22       Impact factor: 3.325

7.  Esthesioneuroblastoma: prognosis and management.

Authors:  A Morita; M J Ebersold; K D Olsen; R L Foote; J E Lewis; L M Quast
Journal:  Neurosurgery       Date:  1993-05       Impact factor: 4.654

8.  Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcome.

Authors:  Gabriel G Malouf; Odile Casiraghi; Eric Deutsch; Joel Guigay; Stéphane Temam; Jean Bourhis
Journal:  Eur J Cancer       Date:  2013-01-10       Impact factor: 9.162

9.  Olfactory Neuroblastoma: Fate of the Neck--A Long-term Multicenter Retrospective Study.

Authors:  Sunny B Nalavenkata; Raymond Sacks; Nithin D Adappa; James N Palmer; Michael T Purkey; Michael D Feldman; Rodney J Schlosser; Carl H Snyderman; Eric W Wang; Bradford A Woodworth; Robert Smee; Thomas E Havas; Richard Gallagher; Richard J Harvey
Journal:  Otolaryngol Head Neck Surg       Date:  2015-12-15       Impact factor: 3.497

10.  Structural and functional features of central nervous system lymphatic vessels.

Authors:  Antoine Louveau; Igor Smirnov; Timothy J Keyes; Jacob D Eccles; Sherin J Rouhani; J David Peske; Noel C Derecki; David Castle; James W Mandell; Kevin S Lee; Tajie H Harris; Jonathan Kipnis
Journal:  Nature       Date:  2015-06-01       Impact factor: 49.962

View more
  2 in total

1.  Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma.

Authors:  Matt Lechner; Yoko Takahashi; Mario Turri-Zanoni; Jacklyn Liu; Nicholas Counsell; Mario Hermsen; Raman Preet Kaur; Tianna Zhao; Murugappan Ramanathan; Volker H Schartinger; Oscar Emanuel; Sam Helman; Jordan Varghese; Jozsef Dudas; Herbert Riechelmann; Susanne Sprung; Johannes Haybaeck; David Howard; Nils Wolfgang Engel; Sarah Stewart; Laura Brooks; Jessica C Pickles; Thomas S Jacques; Tim R Fenton; Luke Williams; Francis M Vaz; Paul O'Flynn; Paul Stimpson; Simon Wang; S Alam Hannan; Samit Unadkat; Jonathan Hughes; Raghav Dwivedi; Cillian T Forde; Premjit Randhawa; Simon Gane; Jonathan Joseph; Peter J Andrews; Gary Royle; Alessandro Franchi; Roberta Maragliano; Simonetta Battocchio; Helen Bewicke-Copley; Christodoulos Pipinikas; Amy Webster; Chrissie Thirlwell; Debbie Ho; Andrew Teschendorff; Tianyu Zhu; Christopher D Steele; Nischalan Pillay; Bart Vanhaesebroeck; Ahmed Mohyeldin; Juan Fernandez-Miranda; Ki Wan Park; Quynh-Thu Le; Robert B West; Rami Saade; R Peter Manes; Sacit Bulent Omay; Eugenia M Vining; Benjamin L Judson; Wendell G Yarbrough; Maddalena Sansovini; Nicolini Silvia; Ilaria Grassi; Alberto Bongiovanni; David Capper; Ulrich Schüller; Selvam Thavaraj; Ann Sandison; Pavol Surda; Claire Hopkins; Marco Ferrari; Davide Mattavelli; Vittorio Rampinelli; Fabio Facchetti; Piero Nicolai; Paolo Bossi; Oswaldo A Henriquez; Kelly Magliocca; C Arturo Solares; Sarah K Wise; Jose L Llorente; Zara M Patel; Jayakar V Nayak; Peter H Hwang; Peter D Lacy; Robbie Woods; James P O'Neill; Amrita Jay; Dawn Carnell; Martin D Forster; Masaru Ishii; Nyall R London; Diana M Bell; Gary L Gallia; Paolo Castelnuovo; Stefano Severi; Valerie J Lund; Ehab Y Hanna
Journal:  Eur J Cancer       Date:  2021-12-31       Impact factor: 10.002

2.  Induction Therapy Prior to Surgical Resection for Patients Presenting with Locally Advanced Esthesioneuroblastoma.

Authors:  Kevin C Miller; John P Marinelli; Jeffrey R Janus; Ashish V Chintakuntlawar; Robert L Foote; Michael J Link; Garret Choby; Jamie J Van Gompel
Journal:  J Neurol Surg B Skull Base       Date:  2020-01-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.